Purpose: To investigate the tear levels of matrix metalloproteinases (MMPs), myeloperoxidase (MPO), and tissue inhibitor of metalloproteinase-1 in eyes after Boston keratoprosthesis type I (B-KPro) implantation and to correlate these markers with the established B-KPro prognostic categories.
T he Boston keratoprosthesis type I (B-KPro) can provide visual rehabilitation in patients with corneal blindness. Eyes with more severe ocular surface diseases, particularly cicatrizing diseases, have poorer outcomes after the implantation of a B-KPro. The increased need for postoperative repair procedures and the faster visual attrition rates observed in these disease categories form the basis for the wellrecognized prognostic categories for B-KPro surgery. 1 Eyes with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have the poorest outcomes, whereas eyes with mucous membrane pemphigoid and chemical burn have intermediate outcomes when compared with eyes with noncicatrizing conditions. Recent case series continue to support this prognostic hierarchy. [2] [3] [4] [5] [6] [7] Corneal melting (sterile keratolysis) after B-KPro also occurs in up to 19% of eyes with noncicatrizing diseases. 2 Corneal melting of the B-KPro carrier graft is a critically important cause of B-KPro failure because it may lead to periprosthetic leaks, B-KPro extrusion, and several other sight-and globe-threatening complications. 3 Matrix metalloproteinases (MMPs) are the enzymes responsible for the corneal collagen and extracellular matrix degradation seen in sterile corneal ulceration. 4 A subset of these enzymes, neutrophil collagenase (MMP-8) and gelatinase-B (MMP-9), as well as myeloperoxidase (MPO), a microbicidal enzyme released during the respiratory burst of neutrophils, have been found in high levels in the tears of patients with SJS/ TEN and mucous membrane pemphigoid. 5 High tear MMP levels have also been found in several other conditions that may eventually necessitate B-KPro surgery. [6] [7] [8] [9] As such, the purpose of this study was to assess the tear levels of MMP, MPO, and tissue inhibitor of metalloproteinase-1 (TIMP-1) in eyes with prior B-KPro implantation and to correlate these enzymes with the underlying diagnoses and B-KPro prognostic categories.
MATERIALS AND METHODS
This cross-sectional study was approved by the Human Studies Committee at the Massachusetts Eye and Ear Infirmary (MEE) and Schepens Eye Research Institute in Boston, MA The study procedures complied with the Health Insurance Portability and Accountability Act and adhered to the tenets of the Declaration of Helsinki. Patients were informed of the nature and design of the study before recruitment, and signed informed consent was obtained.
Study Population
Study participants included patients with prior B-KPro implantation who were followed at the MEE cornea clinic. Subjects were deemed eligible for inclusion if they were older than 18 years and had at least 1 month of stable postoperative follow-up after the B-KPro surgery. Subjects were excluded if they had undergone any intraocular surgery in the preceding month. Pregnancy and breastfeeding were additional exclusion criteria. Study participants were recruited, and their tears were collected during their regular scheduled visits at the MEE cornea clinic between January 2013 and May 2014. Additional tears were collected at subsequent clinic visits for a subset of participants, depending on the availability of the researchers. A complete ocular history and slit lamp examination were performed on the day of tear collection. Slit lamp photographic images were taken of the eyes with active corneal melting. Medical records were reviewed to identify the participants' demographics, prior ocular diagnoses, and surgeries as well as ocular and systemic medications. Patients were grouped by diagnostic category (autoimmune diseases, chemical burns, noncicatrizing diseases) based on the classic prognostic hierarchy after B-KPro implantation. 1
Tear Collection and Processing
A tear wash method was chosen for collecting the tear proteins because it allows harvest of tear fluid from patients with little tear production and increases protein recovery from the ocular surface to allow multiple analyte assays. 10 Tear collection was performed in the afternoon (between 1 and 4 PM) to control for diurnal variation in MMP levels 11, 12 and before any ocular surface manipulation. The tear wash method involved instillation of 60 mL of sterile 0.9% saline solution onto the ocular surface using a sterile plastic micropipette. Participants were instructed to rotate their eyes without blinking, allowing the saline to contact different areas of the ocular surface and thus, collect more protein. The tear wash fluid was collected from the inferior fornix using a micropipette, transferred to a sterile polypropylene tube, and kept on ice. All samples were centrifuged at 15,000 RPM (21,130g) at 4°C for 30 minutes to remove the cellular and mucoid debris. Supernatants were recovered and stored at 280°C for further processing. The tear wash process was performed on both eyes, and each eye was analyzed separately.
Given the variable volume yield using the tear wash method, quantification of the analytes was normalized to protein content, determined using a Micro BCA Protein Assay Kit (Pierce, Rockford, IL), according to the manufacturer's instructions.
Analyses of MMP, MPO, and TIMP-1
The total (proform and active) tear levels of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, and MMP-12 were analyzed simultaneously using the Fluorokine Human MMP MultiAnalyte Profiling Kit (R&D Systems, Minneapolis, MN). Tear MPO and TIMP-1 levels were quantified together using the Fluorokine Human Cardiac MultiAnalyte Profiling Kit (R&D Systems). Samples were processed following the manufacturer instructions and analyzed using a Bio-Rad Bio-Plex analyzer (Bio-Rad, Hercules, CA) powered by Luminex 100 xMAP technology (Luminex Corp, Austin, TX). The median fluorescence intensities were used to calculate the analyte concentrations from a standard curve (in picograms per milliliter) and standardized to micrograms of total protein loaded in the assay. The analyte levels are reported in picograms of analyte per microgram of total protein.
Analysis of Total MMP Activity
A modified protocol of the MMP-9 Fluorometric Drug Discovery Kit (Enzo Life Sciences, Plymouth Meeting, PA) was used as previously described to quantify the total MMP activity. 5 Briefly, a quenched OmniMMP RED fluorogenic substrate (Enzo Life Sciences) was added to each diluted tear sample. Fluorescence was measured at 1-minute intervals for 45 minutes at 540 nm (excitation) and 590 nm (emission) using the Synergy Mx monochromator-based multimode microplate reader (Biotek U.S., Winooski, VT). The slope values were derived from the linear portions of the background and sample curves, and the total MMP activity was calculated as the sample slope minus the background slope in relative fluorescence units per minute (RFU/min) and standardized to micrograms of protein loaded in the assay.
Statistical Analysis
Statistical analysis was performed using Stata/SE 13.1 (StataCorp, College Station, TX). Results were reported as mean 6 standard error of the mean. The nonparametric Mann-Whitney U and Kruskal-Wallis tests were used to compare the analyte levels across diagnostic categories. The Wilcoxon matched-pairs signed-rank test was used to compare paired data between the 2 eyes of patients with bilateral disease and unilateral B-KPro as well as those of patients with bilateral B-KPro. The analyte levels were converted to logarithmic values for correlation analyses using the Spearman rank correlation test. Analysis of variance was used to identify the clinical parameters associated with the MMP-8, MMP-9, and MPO levels and MMP activity. The regression model included patient age, gender, prognostic category, time elapsed since the B-KPro surgery, the presence of a glaucoma drainage device, sterile keratolysis, retroprosthetic membrane or contact lens (CL) deposits, CL type, and the use of topical medications (antibiotics, steroids, prostaglandin analogs, and/ or antiglaucoma) and/or systemic medications (doxycycline, statins, angiotensin-converting enzyme inhibitors, and/or systemic immunomodulation therapy). Univariate and multivariate analyses were performed. A similar multivariate model was built to explore the relationships between the different analyte levels and MMP activity. Statistical significance was determined when the 2-tailed P values were below the 0.05 threshold.
RESULTS

Study Population
A total of 40 patients participated in this study. The mean age was 65 6 3 years (range: 26-97 years). Among these patients, 61% were male. Thirty-three patients had unilateral B-KPro, whereas 7 patients had bilateral B-KPro. The underlying diagnoses leading to B-KPro surgery are outlined in Table 1 . Twenty-eight patients (70%) had bilateral underlying corneal disease (21 patients with unilateral B-KPro and 7 patients with bilateral B-KPro).
The interval between the B-KPro surgery and tear collection was 6.9 6 0.5 years (range: 1 month to 15.6 years). At the time of tear collection, all B-KPro eyes were on topical antibiotic prophylaxis (polymyxin B sulfate-trimethoprim, moxifloxacin, and/or vancomycin 14 mg/mL with benzalkonium chloride). Fifty-three percent of the eyes were on prednisolone acetate 1% used 1 to 4 times per day. Sixty-two percent of the eyes were on topical glaucoma medication at an average of 1.5 medications per eye. Prostaglandin analogs were used in 28% of the eyes. Other medications with potential impact on MMP levels included doxycycline (15%), statins (45%), and angiotensinconverting enzyme inhibitors (36%). 13, 14 Fifteen percent of the eyes were on systemic immunomodulatory therapy.
Eighteen eyes (38%) had undergone prior glaucoma drainage device implantation. Nineteen eyes (83%) had a CL in place. Twenty-three percent of the CLs had visible deposits on the day of tear collection. Previous B-KPro-related complications included retroprosthetic membrane in 27 eyes (57%) and sterile keratolysis (melt) in 13 eyes (28%). Four eyes (9%) had active melting at the time of tear collection.
Tear Sampling
The tear wash method yielded an average of 39 6 2 mL of fluid from the B-KPro eyes and 37 6 2 mL of fluid from the non-B-KPro eyes (P = 0.89). The average protein yield was 44.6 6 6.2 mg in the B-KPro eyes and 40.3 6 5.2 mg in the non-B-KPro eyes (P = 0.61).
MMP, MPO, and TIMP-1 Levels
The mean tear levels of MMPs, MPO, and TIMP-1 from the eyes with B-KPro are presented in Figure 1A . Low levels of MMP-1 (0.3 6 0.1 pg/mg), MMP-2 (3 6 1 pg/mg), MMP-3 (12 6 3 pg/mg), MMP-7 (34 6 5 pg/mg), MMP-12 (0 6 0 pg/mg), and TIMP-1 (32 6 2 pg/mg) were detected. Conversely, MMP-8 (80 6 31 pg/mg), MMP-9 (291 6 77 pg/mg), and MPO (244 6 33 pg/mg) levels were markedly elevated.
Significant differences were noted in the levels of MMP-2, MMP-8, and MMP-9 when comparing the different prognostic categories. The MMP-2 levels in eyes with autoimmune diseases were 5-fold higher than those in eyes with noncicatrizing diseases (P = 0.02). The MMP-8 and MMP-9 levels were 12-and 7-fold higher, respectively, in eyes with chemical burn than in eyes with noncicatrizing diseases (P = 0.02). The MMP-9 level was 4-fold higher in eyes with chemical burn than in eyes with autoimmune disease (P = 0.04).
With respect to specific diagnoses across the B-KPro cohort, the highest levels of MMP-8, MMP-9, and MPO were seen in the B-KPro eyes with chemical burns (474 6 376, 1300 6 635, and 393 6 19 pg/mg, respectively; 3 eyes), topical anesthetic abuse (360, 1406, and 554 pg/mg; 1 eye), neurotrophic/exposure keratopathy (163 6 81, 549 6 217, and 304 6 80 pg/mg; 3 eyes), and SJS/TEN (141 6 116, 426 6 356, and 366 6 177 pg/mg; 4 eyes). The lowest levels of MMP-8, MMP-9, and MPO were seen in eyes with keratoconus (3 6 3, 27 6 26, and 21 6 20 pg/mg; 4 eyes), uveitis-induced corneal edema (0 6 0, 7 6 2, and 47 6 21 pg/mg; 2 eyes), mechanical trauma (5, 31, and 74 pg/mg; 1 eye), and aniridia (6 6 0, 19 6 5, and 165 6 72 pg/mg; 2 eyes).
Total MMP Activity
The total MMP activity is shown in Figure 1B . There were no statistically significant differences between the classic prognostic categories (P = 0.20). The specific diagnoses with the highest total MMP activity were the same as those that exhibited markedly elevated levels of MMP-8, MMP-9, and MPO: chemical burns (381 6 267 RFU$min 21 Correlation Between Tear Levels of MMP-8, MMP-9, and MPO Figure 2 depicts the correlation between MMP-8, MMP-9, and MPO levels in the eyes with B-KPro for the 3 diagnostic categories. MMP-8 and MMP-9 were highly correlated across all eyes with B-KPro regardless of the diagnostic category (r = 0.95, P , 0.001). Strong and statistically significant correlations were also found for each of the diagnostic groups. Strong and statistically significant positive correlation was found between MMP-9 and MPO and between MMP-8 and MPO across all B-KPro eyes and in eyes with noncicatrizing diseases. With smaller sample sizes failing to reach statistical significance, eyes with autoimmune diseases or chemical burn showed only minimal to moderate correlation between MMP-9 and MPO as well as between MMP-8 and MPO.
Regression Analysis
Univariate analysis did not identify any clinical factor with a statistically significant association with MMP-8, MMP-9, and MPO levels or MMP activity. Using multivariate analysis, the clinical factors explained only a small fraction of the analyte levels: MMP-8 (R 2 = 0.47, P = 0.67), MMP-9 (R 2 = 0.55, P = 0.46), MPO (R 2 = 0.68, P = 0.08), and MMP activity (R 2 = 0.46, P = 0.70). The multivariate model identified a significant association between prognostic category and MMP-8 level (P = 0.05). Interestingly, a past or current history of sterile keratolysis was not associated with higher MMP levels.
Multivariate analysis relating the levels of each analyte and MMP activity with one another had better predictive value: MMP-8 (R 2 = 0.98, P , 0.001), MMP-9 (R 2 = 0.97, P , 0.001), MPO (R 2 = 0.45, P = 0.34), and MMP activity (R 2 = 0.91, P , 0.001). Significant association was seen between MMP-8 and MMP-9 levels and total MMP activity. Multivariate models including only these 3 variables had R 2 values between 0.86 and 0.89 (P , 0.001). Finally, MMP-8, MMP-9, and total MMP activity did not show statistically significant association with MPO (P = 0.918, P = 0.571, and P = 0.851, respectively).
Bilateral Disease
The analyte levels and total MMP activity in the tears of patients with bilateral disease and unilateral B-KPro are shown in Figure 3 . Paired data were available for the eyes with SJS/TEN (4 eyes), chemical burn (1 eye), vernal keratoconjunctivitis (1 eye), corneal edema (5 eyes), postinfectious scarring (2 eyes), keratoconus (2 eyes), and thermal burn (1 eye). Of these, the contralateral non-B-KPro eyes had no prior corneal surgery (8 eyes), phthisis (4 eyes), or corneal transplantation (4 eyes). MMP-1 levels were 2-fold higher in eyes with B-KPro (0.25 6 0.06 pg/mg total protein vs. 0.11 6 0.02 pg/mg total protein, P = 0.04). Interestingly, the other MMP levels were not significantly different between the B-KPro and contralateral non-B-KPro eye. Both MMP-8 and MMP-9 tended to be higher in the non-B-KPro eye. Furthermore, there was no significant difference in the analyte levels and total MMP activity between the eyes of patients with bilateral disease and bilateral B-KPro (N = 7).
Repeat Tear Sampling Analysis
Tear collection was performed twice in 17 B-KPro eyes. The interval between repeat tear collections was 261 6 35 days. Repeat tear collection and sample analyses were performed on 10 non-B-KPro eyes. The interval between tear collections was 297 6 41 days. There was no statistically significant difference between repeat measurements of MMP-8, MMP-9, MMP-12, MPO, and TIMP-1 in either group.
Clinical Correlation With Sterile Keratolysis
Although MMP-8 levels correlated with the prognostic category for B-KPro, no other clinical parameter could be clearly associated with tear MMP levels, including the presence of active corneal melting. Figure 4 illustrates the slit lamp appearance and the variability of MMP-8 and MMP-9 levels in 3 eyes with active corneal melting. In 1 patient with aniridia, analyte levels in the setting of extensive, globe-threatening corneal melt (Fig. 4B) were comparable with those obtained 1 year after repeat B-KPro surgery, in the absence of any clinical or optical coherence tomography evidence of melt (MMP-8: 64 pg/mg, MMP-9: 434 pg/mg, and MPO: 2623 pg/mg). 15 
DISCUSSION
This study is the first to report the MMP, MPO, TIMP-1, and total MMP activity levels in the tears of patients with B-KPro. We identified a correlation between MMP-8 level and the prognostic categories for B-KPro surgery as well the presence of particularly high levels of MMP-8 and MMP-9 in B-KPro eyes with chemical burn. MMP levels in tears may be more closely associated with the underlying diagnosis of ocular surface disease than with the presence of a B-KPro. Furthermore, the presence of clinically significant corneal melt did not clearly correlate with higher MMP levels.
Yaghouti and coworkers 1 established a well-defined prognostic hierarchy for B-KPro. Indeed, it is commonly held that severe and ongoing ocular surface inflammation and the associated overexpression of mediators including MMPs lead to an increased vulnerability to corneal melt. 16 Our study identified that, contrary to the above prognostic hierarchy in which autoimmune eyes fare the worst, B-KPro eyes with chemical burns had the highest tear levels of MMP-8 and MMP-9. This difference may be explained by the small sample sizes for the individual diagnostic categories and by the use of systemic immunosuppression in 5 of the 7 patients with autoimmune disease.
Specific diagnoses with high tear levels of MMP-8 and MMP-9 included diseases with a tendency for ocular surface breakdown. The absence of an intact epithelial barrier predisposes the exposed underlying stroma to ulceration by MMP dysregulation and excessive release from inflammatory cells. Conversely, pathologies that tend to spare the ocular surface epithelium had the lowest levels of MMP-8 and MMP-9. Interestingly, the 1 patient with aniridia had low tear MMP levels, despite the presence of limbal stem cell deficiency and significant corneal melting in 1 eye (Fig.  4B ). It has been postulated that the corneal opacification that arises from repeated epithelial erosions and ulcerations in aniridia may be caused by a deficiency in MMP-9 that results in fibrin accumulation and influx of inflammatory cells into the wound bed via chemotactic stimulus and blood vessel extravasation into the stroma. 17 Therefore, it is possible that corneal melting may be the result of collagenolytic enzymes released primarily from stroma-infiltrating inflammatory cells, which are undetectable through tear analysis.
Arafat and colleagues 5 previously reported an association between tear levels of MMP-8, MMP-9, and MPO. Similarly, we demonstrate a strong correlation between tear levels of MMP-8 and MMP-9 across all diagnostic categories, whereas correlation with MPO was moderate. MMP-8 and MMP-9 levels were also correlated with the total MMP activity. MPO, although being responsible for MMP activation through the formation of reactive oxygen species, was not associated with the total MMP activity. 18 The relationship between MMP-8 and MPO, which are both produced by neutrophils, and MMP-9, which may be produced by both epithelium and inflammatory cells, suggest that neutrophils are the predominant and common source of these enzymes. 4, 19 This supports prior studies demonstrating that the MMPs accumulated in tears were produced by granulocytes. 20 Indeed, neutrophils migrate from the limbal vasculature toward the sites of epithelial defect. 21 As degranulation products of these activated neutrophils, MMP-8, MMP-9, and MPO are thus likely to accumulate in the tear film and be recovered using the tear wash method. In contrast, epithelial production of MMP-9 is much more localized and found at the front of the epithelium migrating to cover the wound bed. 22 After B-KPro implantation, a "free" epithelial edge generally persists along the periphery of the front plate. This epithelium may either grow above or below the surface of the B-KPro front plate. 23 The potential impact of these periprosthetic epithelial growth patterns on wound healing mechanisms and MMP-9 expression remain unknown. On the other hand, the presence of stromal inflammation seems to be increased in the presence of a keratoprosthesis. Indeed, the implantation of a miniature keratoprosthesis in the murine model has shown increased expression of tumor necrosis factor a and interleukin-1b as well as increased graftinfiltrating immune cells. 24 The MMP, MPO, and TIMP-1 levels were similar between the eyes of patients with bilateral disease and unilateral B-KPro suggesting that these analytes are more influenced by the underlying disease than by the presence of a B-KPro. The risk of corneal melt after B-KPro is tightly associated with the underlying diagnosis, whereas the relationship between the tear MMP level and the presence of corneal melt remains unclear. The variability of MMP levels in the setting of clinically significant melt as well as the unchanged analyte profile in a patient in the presence and absence of melt may be explained by local differences in the MMP levels. For example, tear MMP levels measured using the tear wash method may be independent of the MMP levels found in the stroma and along the B-KPro stem, where corneal melting occurs. Furthermore, our study did not account for occult corneal melting that can be visible on anterior segment optical coherence tomography but is undetectable at the slit lamp.
The low tear volume and low tear protein recovery are intrinsic limitations of tear collection methods. The tear wash method achieves a higher total protein yield when compared with capillary tear collection. 10 Schirmer strips may also be used to collect tears, but they collect cell protein and unwanted debris from the conjunctival surface in addition to tears. 25 As such, Schirmer strips may not be a valid method of profiling the analytes in tears. Furthermore, tears may have a different profile of mediators when compared with the microenvironment of melting corneas for several reasons, including the presence of a protective CL and of the B-KPro itself.
In conclusion, the eyes with B-KPro may have constitutively high tear levels of MMP-8, MMP-9, and MPO even years after the onset of disease and the B-KPro implantation. These analyte levels correlated more with an underlying diagnosis of ocular surface disease than with the presence of a B-KPro. High tear MMP levels did not clearly associate with sterile keratolysis. Further studies are needed to improve our understanding of the pathophysiology of B-KPro-related melt and expand our armamentarium. This knowledge will be crucial in the development of targeted MMP inhibitors to protect the high-risk B-KPro eyes from the devastating consequences of corneal melting.
